About this Research Topic
Therapeutic antibodies have become a major driving force for the biopharmaceutical industry; therefore, the discovery and development of safe and efficacious antibody leads have become competitive processes. Phage and ribosome display are ideal tools for the generation of such molecules and have already delivered an approved drug as well as a multitude of clinical candidates. Antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including chronic pain, multiple sclerosis, migraines, and neuromuscular disease. In addition, a great number of monoclonal and single-chain fragment variable (scFv) antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these diseases. Untangling the molecular mechanisms of disease allows antibodies to block disease pathways accurately and efficiently with exceptional target specificity, minimizing non-specific effects. On the other hand, accumulating experience shows that antibodies may carry class-specific and target-associated risks.
Therapeutic antibodies have become a major driving force for the biopharmaceutical industry; therefore, the discovery and development of safe and efficacious antibody leads have become competitive processes. Phage and ribosome display are ideal tools for the generation of such molecules and have already delivered an approved drug as well as a multitude of clinical candidates. Antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including chronic pain, multiple sclerosis, migraines, and neuromuscular disease. In addition, a great number of monoclonal and single-chain fragment variable (scFv) antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these diseases. Untangling the molecular mechanisms of disease allows antibodies to block disease pathways accurately and efficiently with exceptional target specificity, minimizing non-specific effects. On the other hand, accumulating experience shows that antibodies may carry class-specific and target-associated risks.
In this Research Topic, we will focus on phage and ribosome display and its use for discovering novel antibodies, the development of new phage and ribosome display techniques, optimization, humanization and affinity maturation approaches, or its utilization in novel applications in neurological therapeutics.
This Research Topic welcomes submissions including, but not limited to:
● Murine Antibodies
● Chimeric Antibodies
● Humanized Antibodies
● Fully Human Monoclonal Antibodies
● Mechanism of Action
● Doses, Routes of Administration and Pharmacokinetics
● Indications in Neurology
● Safety Considerations of Abs
Therapeutic antibodies have become a major driving force for the biopharmaceutical industry; therefore, the discovery and development of safe and efficacious antibody leads have become competitive processes. Phage and ribosome display are ideal tools for the generation of such molecules and have already delivered an approved drug as well as a multitude of clinical candidates. Antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including chronic pain, multiple sclerosis, migraines, and neuromuscular disease. In addition, a great number of monoclonal and single-chain fragment variable (scFv) antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these diseases. Untangling the molecular mechanisms of disease allows antibodies to block disease pathways accurately and efficiently with exceptional target specificity, minimizing non-specific effects. On the other hand, accumulating experience shows that antibodies may carry class-specific and target-associated risks.
In this Research Topic, we will focus on phage and ribosome display and its use for discovering novel antibodies, the development of new phage and ribosome display techniques, optimization, humanization and affinity maturation approaches, or its utilization in novel applications in neurological therapeutics.
This Research Topic welcomes submissions including, but not limited to:
● Murine Antibodies
● Chimeric Antibodies
● Humanized Antibodies
● Fully Human Monoclonal Antibodies
● Mechanism of Action
● Doses, Routes of Administration and Pharmacokinetics
● Indications in Neurology
● Safety Considerations of Abs
Keywords: Phage and ribosome display, display technologies, monoclonal antibodies, recombinant antibody formats, humanization and affinity maturation, optimization, therapeutics, Chronic pain, Alzheimer's disease, Duchene's muscular dystrophy, Parkinson's disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
